|
Title
|
|
|
|
Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Aims: To evaluate the efficacy and tolerability of flexible-dose fesoterodine in subjects with overactive bladder (OAB) who were dissatisfied with previous tolterodine treatment. Methods: This was a 12-week, open-label, flexible-dose study of adults with OAB (¡Ý 8 micturitions and ¡Ý 3 urgency episodes per 24 h) who had been treated with tolterodine (immediate- or extended-release) for OAB within 2 years of screening and reported dissatisfaction with tolterodine treatment. Subjects received fesoterodine 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on the subject's and physician's subjective assessment of efficacy and tolerability. Subjects completed 5-day diaries, the Patient Perception of Bladder Condition (PPBC) and the Overactive Bladder Questionnaire (OAB-q) at baseline and week 12 and rated treatment satisfaction at week 12 using the Treatment Satisfaction Question (TSQ). Safety and tolerability were assessed. Results: Among 516 subjects treated, approximately 50% opted for dose escalation to 8 mg at week 4. Significant improvements from baseline to week 12 were observed in micturitions, urgency urinary incontinence episodes, micturition-related urgency episodes and severe micturition-related urgency episodes per 24 h (all p < 0.0001). Approximately 80% of subjects who responded to the TSQ at week 12 reported satisfaction with treatment; 38% reported being very satisfied. Using the PPBC, 83% of subjects reported improvement at week 12 with 59% reporting improvement ¡Ý 2 points. Significant improvements from baseline (p < 0.0001) exceeding the minimally important difference (10 points) were observed in OAB-q Symptom Bother and Health-Related Quality of Life (HRQL) scales and all four HRQL domains. Dry mouth (23%) and constipation (5%) were the most common adverse events; no safety issues were identified. Conclusion: Flexible-dose fesoterodine significantly improved OAB symptoms, HRQL, and rates of treatment satisfaction and was well tolerated in subjects with OAB who were dissatisfied with prior tolterodine therapy. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
International journal of clinical practice. - London
| |
|
Publication
|
|
|
|
London
:
2009
| |
|
ISSN
|
|
|
|
1368-5031
| |
|
DOI
|
|
|
|
10.1111/J.1742-1241.2009.02035.X
| |
|
Volume/pages
|
|
|
|
63
:4
(2009)
, p. 560-567
| |
|
ISI
|
|
|
|
000264241100008
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|